Monkeypox Outbreak Draws Attention to Tonix Pharma's (TNXP) Vaccine Programs - Noble Capital

Noble Capital analyst Robert LeBoyer reiterated an Outperform rating and adjusted the price target on Tonix Pharma (NASDAQ: TNXP) to $10.00 as the Monkeypox outbreak attracts attention to the company's vaccine programs.

LeBoyer notes Tonix has a proprietary vaccine program for monkeypox and smallpox.

"We have viewed TNX-801 development as a program that uses the proprietary BPIV vaccine vector with scHPXV," LeBoyer comments. "Once approved, the vaccine could be sold to Department of Health and Human Service for the Strategic National Stockpile. We have not included any revenues for TNX-801 in our models. We have adjusted our earnings estimates and price targets for the 1-for-32 reverse split, with a new price target of $10 per share."

For an analyst ratings summary and ratings history on Tonix Pharma click here. For more ratings news on Tonix Pharma click here.

Shares of Tonix Pharma closed at $2.35 yesterday.

You May Also Be Interested In

• CACI International (CACI) PT Raised to $440 at Stifel
• Inter Parfums (IPAR) PT Lowered to $172 at Piper Sandler
• Intermediate Capital Group (ICP:LN) (ICGUF) PT Raised to GBP22.50 at Citi